Analysen von Michael Leuchten
| 10.07.20 | Bayer buy | UBS AG | |
| 09.07.20 | Bayer buy | UBS AG | |
| 08.07.20 | Bayer buy | UBS AG | |
| 01.07.20 | Bayer buy | UBS AG | |
| 25.06.20 | Sartorius vz. Sell | UBS AG | |
| 25.06.20 | Bayer buy | UBS AG | |
| 23.06.20 | Bayer buy | UBS AG | |
| 15.06.20 | Bayer buy | UBS AG | |
|
Werbung
|
|||
| 10.06.20 | Bayer buy | UBS AG | |
| 08.06.20 | AstraZeneca Sell | UBS AG | |
| 08.06.20 | Sartorius vz. Sell | UBS AG | |
| 05.06.20 | Novo Nordisk Neutral | UBS AG | |
| 05.06.20 | Bayer buy | UBS AG | |
| 04.06.20 | AstraZeneca Sell | UBS AG | |
| 27.05.20 | AstraZeneca Sell | UBS AG | |
| 25.05.20 | AstraZeneca Sell | UBS AG | |
| 22.05.20 | AstraZeneca Sell | UBS AG | |
| 14.05.20 | Novo Nordisk Neutral | UBS AG | |
| 14.05.20 | Roche buy | UBS AG | |
| 14.05.20 | Merck Neutral | UBS AG | |
| 13.05.20 | Roche buy | UBS AG | |
| 11.05.20 | Novo Nordisk Neutral | UBS AG | |
| 06.05.20 | Novo Nordisk buy | UBS AG | |
| 29.04.20 | AstraZeneca Sell | UBS AG | |
| 28.04.20 | Roche buy | UBS AG | |
| 27.04.20 | Bayer buy | UBS AG | |
| 23.04.20 | Roche buy | UBS AG | |
| 22.04.20 | Sartorius vz. Neutral | UBS AG | |
| 17.04.20 | Novo Nordisk buy | UBS AG | |
| 15.04.20 | Novo Nordisk buy | UBS AG | |
| 24.03.20 | Roche buy | UBS AG | |
| 23.03.20 | Novo Nordisk buy | UBS AG | |
| 10.03.20 | Merck Neutral | UBS AG | |
| 09.03.20 | AstraZeneca Sell | UBS AG | |
| 06.03.20 | Merck Neutral | UBS AG | |
| 03.03.20 | Bayer buy | UBS AG | |
| 27.02.20 | Bayer buy | UBS AG | |
| 18.02.20 | AstraZeneca Sell | UBS AG | |
| 07.02.20 | Roche buy | UBS AG | |
| 06.02.20 | Novo Nordisk Neutral | UBS AG | |
| 03.02.20 | AstraZeneca Sell | UBS AG | |
| 30.01.20 | Roche buy | UBS AG | |
| 17.01.20 | Novo Nordisk Neutral | UBS AG | |
| 10.01.20 | Roche buy | UBS AG | |
| 12.12.19 | AstraZeneca Sell | UBS AG | |
| 09.12.19 | AstraZeneca Sell | UBS AG | |
| 09.12.19 | Sartorius vz. Neutral | UBS AG | |
| 06.12.19 | Novo Nordisk Neutral | UBS AG | |
| 03.12.19 | AstraZeneca Sell | UBS AG | |
| 26.11.19 | Merck Neutral | UBS AG | |